2025-09-23 – Press Releases – www.prnewswire.com
CHENGDU, China, Sept. 23, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) announced that a new drug application (NDA) for the Company’s small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for…
